Viewing Study NCT06458374



Ignite Creation Date: 2024-06-16 @ 11:52 AM
Last Modification Date: 2024-10-26 @ 3:32 PM
Study NCT ID: NCT06458374
Status: RECRUITING
Last Update Posted: 2024-06-13
First Post: 2024-06-07

Brief Title: ATTR Cardiac Amyloidosis in a Selected Population
Sponsor: Helse Møre og Romsdal HF
Organization: Helse Møre og Romsdal HF

Study Overview

Official Title: Prevalence and Long Tem Follow Up of ATTR Cardiac Amyloidosis in a Selected Population of Patients Operated on Carpal Tunnel Syndrome
Status: RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients operated for carpal tunnel syndrome CTS at Ålesund Hospital 200 patients will have a biopsy to diagnose ATTR amyloidosis Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically
Detailed Description: Biopsy proven ATTR vwt amyloidosis inpatients operated with CTS will undergo standard guidelines recommended examinations as 99mTcDPD SPECT CT echocardiography ECG Holter genetic testing vwt and lab testing and CMRI as indicated Exclusion of light chain disease will be done

All patients will be followed at least yearly as indicated by guidelines ESC and patients with development of cardiac amyloidosis will get standard treatment in accordance with guidelines and as approved by the Norwegian government All patients will be followed for 10 years

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None